Navigation
Marktaussichten Aktienscreener Dividendenkalender Veranstaltungskalender Bewertung der Aktien Marktnachrichten
Kostenlos ausprobieren

Mersana Therapeutics

NASDAQ MRSN
$2.73 0.0000 0.0000%
Today share price
Vereinigte Staaten von Amerika
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Показатель: 20 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

331.49M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
185.56M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
2.54
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
121.42M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
17.67 %

Upcoming events Mersana Therapeutics

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Mersana Therapeutics

Stock analysis Mersana Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-2.46 28.88
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
8.98 4.03
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-1.36 11.32
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
1.07 0.25
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-481.73 10.75

Price change Mersana Therapeutics per year

8.79$ 29.09$
Min Max

Summary analysis Mersana Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Mersana Therapeutics

Revenue and net income Mersana Therapeutics

All parameters

Stock news Mersana Therapeutics

All news
31 Oktober 2023 в 19:35

Mersana Therapeutics Shares Rise 8% After FDA Lifts Clinical Hold for Cancer Treatment

31 Oktober 2023 в 19:35

Mersana Therapeutics Shares Rise 8% After FDA Lifts Clinical Hold for Cancer Treatment

27 Juli 2023 в 20:10

Mersana Therapeutics Shares Plumb New Depths After UpRi Failure >MRSN

27 Juli 2023 в 20:10

Mersana Therapeutics Shares Plumb New Depths After UpRi Failure >MRSN

27 Juli 2023 в 14:40

Mersana Therapeutics Shares Plunge Premarket on UpRi Failure

15 Juni 2023 в 15:05

Mersana Therapeutics stock craters after FDA halts trials of ovarian cancer treatment after bleeding events

15 Juni 2023 в 14:55

Mersana Therapeutics Says 2 Drug Trials Put on Partial Hold

15 Juni 2023 в 14:55

Mersana Therapeutics Says 2 Drug Trials Put on Partial Hold

13 März 2023 в 14:55

Mersana Therapeutics Study on FDA Hold After Patient Death >MRSN

13 März 2023 в 14:55

Mersana Therapeutics Study on FDA Hold After Patient Death >MRSN

23 Dezember 2022 в 00:30

Mersana Therapeutics Shares Rise 5.2% on Agreement with Merck KGaA Subsidiary

23 Dezember 2022 в 00:30

Mersana Therapeutics Shares Rise 5.2% on Agreement with Merck KGaA Subsidiary

21 November 2022 в 15:50

Mersana Therapeutics started at buy with $12 stock price target at Truist

9 August 2022 в 20:46

Mersana Therapeutics Shares Jump 31% ON Collaboration Deal With GSK

9 August 2022 в 20:46

Mersana Therapeutics Shares Jump 31% ON Collaboration Deal With GSK

9 August 2022 в 01:00

Mersana Therapeutics Shares Rise 14% After News of GSK Deal

9 August 2022 в 01:00

Mersana Therapeutics Shares Rise 14% After News of GSK Deal

3 Februar 2022 в 17:05

Mersana Therapeutics Shares Rise on Collaboration With Janssen Biotech

3 Februar 2022 в 17:01

Mersana Therapeutics Shares Rise on Collaboration With Janssen Biotech

10 September 2021 в 21:00

Mersana Therapeutics Down 37% After Update on Lead Product Candidate UpRi

About company Mersana Therapeutics

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Address:
840 Memorial Drive, Cambridge, MA, United States, 02139
Company name: Mersana Therapeutics
Issuer ticker: MRSN
ISIN: US59045L1061
Country: Vereinigte Staaten von Amerika
Exchange: NASDAQ
Currency: $
IPO date: 2017-06-28
Sector: Healthcare
Industry: Biotechnology
Site: https://www.mersana.com

On which stock exchange are Mersana Therapeutics (MRSN) stocks traded?

Mersana Therapeutics (MRSN) stocks are traded on NASDAQ.

What is the ticker of Mersana Therapeutics stocks (MRSN)?

The stock ticker of Mersana Therapeutics’s stocks or in other words, the code is MRSN. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Mersana Therapeutics (MRSN) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Mersana Therapeutics (MRSN) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Mersana Therapeutics (MRSN) stocks traded?

Mersana Therapeutics (MRSN) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Mersana Therapeutics (MRSN) stocks today?

The current price of Mersana Therapeutics stocks on 20.05.2024 is 2.73 dollars. per share.

What is the dynamics of Mersana Therapeutics (MRSN) stocks from the beginning of the year?

Mersana Therapeutics (MRSN) quotes have increased by 20.26% from the beginning of the year up to 2.73 dollars. per 1 stocks.

How much did Mersana Therapeutics (MRSN) stocks increase in мае 2024?

This month Mersana Therapeutics (MRSN) quotes have increased by -18.99% to 2.73 dollars. per share.

How much are Mersana Therapeutics (MRSN) stocks worth?

Today, on October, 20.05.2024 Mersana Therapeutics’s (MRSN) stocks cost 2.73 dollars..

What is the market capitalization of Mersana Therapeutics (MRSN)?

Capitalization is the market value of Mersana Therapeutics (MRSN) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 20.05.2024, the market capitalization of Mersana Therapeutics (MRSN) is estimated at about 331490122 dollars.